Massachusetts Financial Services Co. MA raised its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 27.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 660,391 shares of the company's stock after acquiring an additional 140,690 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 1.16% of Harmony Biosciences worth $26,416,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Intech Investment Management LLC acquired a new stake in Harmony Biosciences in the third quarter valued at $388,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Harmony Biosciences in the third quarter valued at about $359,000. Quest Partners LLC raised its position in shares of Harmony Biosciences by 137.6% during the third quarter. Quest Partners LLC now owns 35,723 shares of the company's stock worth $1,429,000 after acquiring an additional 20,689 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Harmony Biosciences in the third quarter worth approximately $235,000. Finally, CWA Asset Management Group LLC bought a new stake in Harmony Biosciences in the third quarter valued at approximately $576,000. Institutional investors own 86.23% of the company's stock.
Harmony Biosciences Stock Up 0.3 %
Shares of NASDAQ HRMY traded up $0.12 during midday trading on Tuesday, hitting $34.83. 377,446 shares of the stock traded hands, compared to its average volume of 477,580. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The business has a 50 day moving average price of $35.45 and a two-hundred day moving average price of $33.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The company has a market cap of $1.99 billion, a PE ratio of 16.51, a P/E/G ratio of 0.63 and a beta of 0.77.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business's revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.63 earnings per share. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.
Insider Buying and Selling at Harmony Biosciences
In other Harmony Biosciences news, insider Jeffrey Dierks sold 21,496 shares of the stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 30.80% of the company's stock.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Raymond James restated an "outperform" rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Needham & Company LLC restated a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday, October 29th. UBS Group assumed coverage on Harmony Biosciences in a report on Tuesday, September 10th. They set a "buy" rating and a $56.00 price target for the company. Mizuho boosted their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Thursday, October 10th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Harmony Biosciences has an average rating of "Moderate Buy" and an average price target of $47.00.
View Our Latest Research Report on HRMY
Harmony Biosciences Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
